SK Biopharmaceuticals Acquires Full Control of U.S. R&D Unit with $36 Million Investment to Advance Cancer Pipeline
核心洞察
SK Biopharmaceuticals (搜索) is acquiring 100% ownership of SK Life Science Labs (搜索) through a $36 million capital increase to strengthen its anticancer drug development capabilities.
The investment leverages Xcopri's record-breaking sales of $442 million in 2024 to create a self-sustaining R&D ecosystem that funds future drug development.
SK Life Science Labs (搜索) has built a pipeline of more than seven anticancer drug candidates using targeted protein degradation technology, with plans to file IND applications this year.
SK Biopharmaceuticals (搜索) is acquiring 100% ownership of its U.S. subsidiary SK Life Science Labs (搜索) through a 51.25 billion won ($36 million) capital increase, marking a strategic move to consolidate its next-generation anticancer drug development operations. The South Korean pharmaceutical company's board approved the acquisition on May 6, 2024, as part of a broader strategy to build a "self-sustaining R&D ecosystem" powered by the commercial success of its epilepsy drug Xcopri.
Strategic Consolidation for Enhanced Efficiency
The acquisition simplifies SK Biopharmaceuticals (搜索)' previously complex governance structure by establishing SK Life Science Labs (搜索) as a wholly-owned subsidiary. The company acquired an additional 40% stake from holding company SK Inc (搜索). while securing new shares through the capital increase, creating an independent operational system spanning R&D to commercialization in the United States.
This restructuring allows SK Biopharmaceuticals (搜索) to fully control both its sales entity SK Life Science and research entity SK Life Science Labs (搜索), maximizing management efficiency across its U.S. operations.
Xcopri Success Fuels Investment Strategy
The capital increase is underpinned by Xcopri's dominant market position in epilepsy treatment. The drug recorded all-time high sales of 630.3 billion won in the U.S. market last year, representing a 43.7% year-over-year increase. SK Biopharmaceuticals (搜索) has set this year's annual sales target for Xcopri at approximately 800 billion won, expecting continued growth momentum.
The stable cash flow from Xcopri provides a financial foundation for self-funding the entire drug development process, with industry observers noting that the company has established a self-sustaining R&D model based on annual selling, general, and administrative expenses of approximately 570 billion won.
Advanced Cancer Technology Platform
SK Life Science Labs (搜索) was established in 2023 following SK Biopharmaceuticals (搜索)' acquisition of Proteovant (搜索), internalizing next-generation anticancer technology including a targeted protein degradation (TPD) platform that fundamentally eliminates disease-causing proteins. The subsidiary has built a pipeline of more than seven anticancer drug candidates targeting solid tumors and specific cancer gene mutations using its proprietary MOPED platform, currently in preclinical development.
SK Biopharmaceuticals (搜索) is directly leading radiopharmaceutical therapy (RPT) development while advancing TPD technology through its subsidiary, positioning both technologies as dual growth pillars for the company's evolution into a "global big biotech."
Clinical Development Timeline
The capital increase funds will be specifically allocated for toxicity studies and chemistry, manufacturing, and controls (CMC) development to complete preclinical processes and file Investigational New Drug (IND) applications within this year. SK Biopharmaceuticals (搜索) has set an ambitious target to enter clinical trials with at least two new candidates annually through 2029.
"We are expanding investments in new growth engines based on Xcopri's U.S. sales growth," an SK Biopharmaceuticals (搜索) official stated. "With this funding, we plan to focus on advancing anticancer drug candidates into clinical trials and achieving technological milestones within this year."
Strategic Vision Beyond CNS Portfolio
CEO Lee Dong-hoon has declared the company's ambition to evolve beyond its traditional central nervous system portfolio, leveraging RPT and TPD technologies as the foundation for becoming a global biotechnology leader. This strategic pivot represents a significant expansion from the company's established epilepsy treatment franchise into the broader oncology market.
The investment demonstrates SK Biopharmaceuticals (搜索)' commitment to minimizing external funding dependence while maximizing the commercial potential of its existing assets to fuel future innovation in cancer therapeutics.